Jeffrey Roberts Posted February 8, 2022 Report Share Posted February 8, 2022 LAVAL, QC, Feb. 8, 2022 /CNW Telbec/ - Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE® (plecanatide). TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and is the first treatment brought to market in Canada by the gastrointestinal division of the Company. Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment, but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms. >> Read full press release Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.